# ERIS Lifesciences share price today (ERIS Lifesciences Ltd, NSE: ERIS)

> ERIS Lifesciences share price today: ₹1,177.70 at the NSE close on 3 November 2026, down 26.0% in a year. ERIS Lifesciences (NSE: ERIS) is worth ₹16,345 crore, trades at a P/E of 21.9 and has closed between ₹1,095.50 and ₹1,666.00 over the past 52 weeks. > ERIS Lifesciences Ltd's earnings have grown faster than its share price. Earnings per share grew +73.1% in a year while the price moved −26.0%. ERIS · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/eris-lifesciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from fewer quarters than usual
- Price: ₹1,177.70 (−26.0% in a year)
- P/E: 21.9× (lower than 88% of the last 9.3 years)
- Revenue (Sep 2026): ₹892 Cr (+12.6% on a year ago)
- Profit (Sep 2026): ₹187 Cr (+39.6% on a year ago)
- Operating margin: 35.0% (−1.0 points on a year ago)
- ROCE: 14%, FY26
- Profit that came in as cash: 147%, last 3 years

The main question: yearly earnings per share moved +73.1% while the share price moved −26.0%. ## What is the ERIS Lifesciences share price today? ERIS Lifesciences Ltd's share price was ₹1,177.70 at the close on 3 November 2026. It has been falling for 40 weeks. That is 12.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,096 and ₹1,666, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running. Over the last 9.3 years the share price moved +96% while the NIFTY 500 moved +159%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at ERIS Lifesciences this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), foreign funds (FIIs) cut their stake for 6 quarters in a row and profit up on a year earlier for 7 quarters in a row. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹892 crore, +12.6% on a year earlier. 2. Foreign funds (FIIs) cut their stake for 6 quarters in a row From 8.4% to 5.7% of the company by the September 2026 quarter. 3. Profit up on a year earlier for 7 quarters in a row In the September 2026 quarter profit was ₹187 crore, +39.6% on a year earlier. ## What are ERIS Lifesciences' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), ERIS Lifesciences reported revenue of ₹892 crore, up 12.6% from ₹792 crore a year earlier, and a profit of ₹187 crore, up 39.6% from ₹134 crore. ### ERIS Lifesciences results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹892 crore | ₹792 crore | +12.6% |
| Profit | ₹187 crore | ₹134 crore | +39.6% |
| Earnings per share | ₹13.25 | ₹8.82 | +50.2% |
| Operating margin | 35.0% | 36.0% | −1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). ERIS Lifesciences' management discussed these results on a call held on 26 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the ERIS Lifesciences share price history? ERIS Lifesciences closed at ₹1,177.70 on 3 November 2026, down 26.0% from ₹1,591.70 a year earlier (31 October 2025) and up 44.4% over five years. Its highest weekly close since June 2017 was ₹1,808.40 on 1 August 2025. ### ERIS Lifesciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,095.50 | +7.5% |
| 1 month ago · 1 Oct 2026 | ₹1,189.80 | −1.0% |
| 6 months ago · 30 Apr 2026 | ₹1,322.90 | −11.0% |
| 1 year ago · 31 Oct 2025 | ₹1,591.70 | −26.0% |
| 3 years ago · 3 Nov 2023 | ₹873.00 | +34.9% |
| 5 years ago · 4 Nov 2021 | ₹815.30 | +44.4% |
| Earliest weekly close in our records · 30 Jun 2017 | ₹601.30 | +95.9% |
| Highest weekly close since June 2017 · 1 Aug 2025 | ₹1,808.40 | −34.9% |
| Lowest weekly close since June 2017 · 3 Apr 2020 | ₹369.95 | +218.3% |
| 52-week high (weekly close) · 21 Nov 2025 | ₹1,666.00 | −29.3% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹1,095.50 | +7.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (492 weekly closes from 30 June 2017 to 3 November 2026.)

## What is the latest news on ERIS Lifesciences? 3 Nov 2026: ERIS Lifesciences closed at ₹1,177.70, up 7.5% on the week and down 1.0% on the month. 26 Oct 2026: ERIS Lifesciences held its results call for July to September 2026. Management guided: H2 operating margin around 35% now at 36% with further gross and operating profit gains ahead. ### Earlier

- Results for July to September 2026: Revenue up 12.6% and profit up 39.6% on a year earlier. - 29 May 2026: ex-date for an interim dividend of ₹7.21 a share. ## What dividend does ERIS Lifesciences pay? ERIS Lifesciences paid ₹7.21 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.61% at the ₹1,177.70 close on 3 November 2026. The last was an interim dividend of ₹7.21 a share, ex-date 29 May 2026. ### ERIS Lifesciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 29 May 2026 | ₹7.21 | Interim | same day |
| 13 Feb 2025 | ₹7.35 | Interim | same day |
| 11 Aug 2022 | ₹7.35 | Interim | 16 Aug 2022 |
| 5 Aug 2021 | ₹6.01 | Interim | 6 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 3 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. ERIS Lifesciences Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did ERIS Lifesciences management say on the latest results call? On the call for July to September 2026, held on 26 October 2026, ERIS Lifesciences' management guided: H2 operating margin around 35% now at 36% with further gross and operating profit gains ahead. > “The market is ramping up well, and I feel that the market might double next year from where we started. It looks like we are now talking about 40-45 crores a month. I think next year we should be doing around 80-90 crores a month.”
> Amit Bakshi, on the call for July to September 2026

### What management guided

- 100 basis points each from Bhopal and Zorvia over next two quarters to 150-200 basis points at full Bhopal Q2 next year shift, ramp from Q1. - December quarter Swiss sales within 5% of last year at 25% margin; November shutdown with re-invite by year end; PV batches March-April, turnaround after Q1. - Net debt paydown ₹150-200 crore this year and ₹400-500 crore next year; H2 capital spending ₹100 crore then sharp reduction. - Effective tax rate 20-21% this year and next; Bhopal 15% levy versus 37% on outsourcing; added depreciation ₹30 crore on ₹200-300 crore capitalisation. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/6607-26-Oct-2026.pdf). (From the call for July to September 2026, 26 October 2026.)

## What to watch in ERIS Lifesciences' next results? When ERIS Lifesciences reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Bhopal volume shift from negligible base with flagged gross uplift and operating profit flow-through visible in print. - What to check (from the call)
- Bhopal volume shift from negligible base with flagged gross uplift and operating profit flow-through visible in print. - Zorvia royalty inflow from next quarter with chronic mix step-up and margin impact as licensed book exits. - Swiss November shutdown execution, auditor re-invite progress and December quarter resilience with partner development continuity intact. - Semaglutide prescription leadership retention and visceral-fat study publication within guided window supporting value rank improvement. ## Which stock lists is ERIS Lifesciences on? ERIS Lifesciences is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 409](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 16096.721549636804](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is ERIS Lifesciences profitable? ERIS Lifesciences Ltd earned ₹187 Cr of net profit in the Sep 2026 quarter, +39.6% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹648 Cr. Over 10 years profit has grown 17.0% a year on average. That is 21.0% of the quarter's revenue. The same quarter a year earlier earned ₹134 Cr. For the full year, FY26 profit was ₹648 Cr (+72.8% on the year before). Why profit moved: revenue changed +12.6% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +63.2% and revenue +11.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does ERIS Lifesciences make, and is it growing? ERIS Lifesciences Ltd reported ₹892 Cr of revenue in the Sep 2026 quarter, +12.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 18.0% a year on average. The last full year, FY26, came in at ₹3,129 Cr. The last four reported quarters add to ₹3,329 Cr. FY26 revenue was ₹3,129 Cr, +8.1% on the year before. Recent pace: the last four quarters grew +11.0% on average, against 18.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.1%, against +15.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +60.3%, against +39.9% a year (accelerating). ## How much of every ₹100 of sales does ERIS Lifesciences keep? ERIS Lifesciences Ltd's operating margin was 35.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 19.0% and 38.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.8 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is ERIS Lifesciences' profit turning into cash? Over the last 3 years, 147% of ERIS Lifesciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹538 Cr of operating cash against ₹648 Cr of profit. After ₹266 Cr of spending on assets, ₹272 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 147% of profit came in as cash: the cash cycle got 99 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 4.6× depreciation over three years. The next section checks what that spending is building. ## Where does ERIS Lifesciences' cash go? ERIS Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 129 days in FY26, up from 30 days in FY21. It spent ₹3,547 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 200 days on average. At FY26 sales of ₹3,129 Cr, each day of that cycle ties up about ₹8.6 Cr, so roughly ₹1,106 Cr is tied up in the business at any time. FY26: customers took 79 days to pay and stock sat for 200 days, about 6.6 months of sales sitting as stock, for a full cycle of 129 days, longer than FY21's 30. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 200 days. Customers pay about 79 days after that. Suppliers are paid at 151 days. Together that makes the 129-day cycle. Spending on assets: ₹3,547 Cr over the last 3 years, against ₹778 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹171 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is ERIS Lifesciences' P/E ratio, and how does it compare with its own history? ERIS Lifesciences Ltd's P/E is 21.9×, near the low end of its own history: it has been lower only 12% of the time. Its usual P/E (the middle reading) is 29.5×, over 9.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹51.18. Why the multiple is where it is: over the past year earnings per share moved +73.1% while the price moved −26.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +7.6% a year; about +13.8% a year came from earnings growth and about −6.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 11% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the ERIS Lifesciences business getting better or worse? ERIS Lifesciences Ltd's business is getting better. EPS growth hit its low 6 quarters ago at −10.2% and has recovered to +67.7%, with ROCE steady at 14.0%. This is based on 9 quarters of 4 measures, with some gaps. Why it matters: a lasting rise from a low is what this page is built to show. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does ERIS Lifesciences earn on its capital? ERIS Lifesciences Ltd earned a ROCE of 14% in FY26. That is up from a low of 11% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 20.7% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 20.7% net margin × 0.44× asset turnover × 1.83× leverage (assets divided by equity) ≈ 16.7% on equity. The margin does most of the work; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 11% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does ERIS Lifesciences have too much debt? ERIS Lifesciences Ltd had ₹2,359 Cr of borrowings against ₹3,903 Cr of equity in FY26, so its debt is 0.60× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹7.0 Cr to ₹2,359 Cr. Over the last 3 of those years it spent ₹3,547 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 11% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the ERIS Lifesciences shareholding pattern? Foreign institutions cut their stake in ERIS Lifesciences Ltd by 2.3 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 5.7% of the company. Domestic institutions moved +1.6 points over the same period, to 20.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −2.3 points over 8 quarters, to 5.7%; Domestic institutions: +1.6 points over 8 quarters, to 20.2%; Promoters: −0.1 points over 8 quarters, to 54.7%. Why the owners changed: foreign institutions moved −2.3 points and domestic institutions +1.6 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is ERIS Lifesciences from balance-sheet trouble? For ERIS Lifesciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does ERIS Lifesciences rank in its industry? 56.1 out of 100, rank 17 of 44 in Pharma - Formulators, with 67% of the evidence available. ERIS Lifesciences Ltd scores 56.1 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 17. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.4 + 14.4 + 12.8 + 7.5 = 56.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is ERIS Lifesciences compared with? ERIS Lifesciences ranks 17 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 56.1 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. ERIS Lifesciences Ltd this page ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 11.1% · Profit 60.3% · Operating margin change -1 points · 95% evidence Capital efficiency 14.4/25 · ROCE 14.1% · Operating margin 35% · 76% evidence Valuation 12.8/20 · P/E 21.5× · PEG n/a · 50% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -12.6% · 1 year -27.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 21.4 + 14.4 + 12.8 + 7.5 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to ERIS Lifesciences in size? ERIS Lifesciences is the 19th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Wockhardt, Rubicon Research and Caplin Point Laboratories. Just below it: Alembic Pharmaceuticals, Natco Pharma and Marksans Pharma. ### Pharma - Formulators companies close in size

1. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) ₹30,895 crore
2. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) ₹26,660 crore
3. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) ₹17,677 crore
4. ERIS Lifesciences Ltd ₹16,044 crore
5. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹15,683 crore
6. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹15,348 crore
7. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) ₹13,876 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Anant Raj Ltd](https://www.sectoralpha.in/stocks/anant-raj-ltd) ₹16,097 crore · Data Centre
2. [Choice International Ltd](https://www.sectoralpha.in/stocks/choice-international-ltd) ₹16,070 crore · Finance - Capital Markets - Brokers
3. ERIS Lifesciences Ltd ₹16,044 crore
4. [Shadowfax Technologies Ltd](https://www.sectoralpha.in/stocks/shadowfax-technologies-ltd) ₹15,956 crore · Logistics
5. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore · Pharma - MNC bulk Drugs

## What else do people ask about ERIS Lifesciences? ### What is ERIS Lifesciences's share price today? ERIS Lifesciences Ltd's share price is ₹1,177.70, −26.0% over the past year. The whole company is worth ₹16,345 Cr on the market. In the last 52 weeks it traded between ₹1,096 to ₹1,666; today it is 14% of the way up from the low, 12.8% below its 200-day average (as of 3 November 2026). ### What were ERIS Lifesciences's latest quarterly results? ERIS Lifesciences Ltd reported revenue of ₹892 Cr and net profit of ₹187 Cr for the Sep 2026 quarter. Revenue rose 12.6% and profit rose 39.6% compared with a year earlier. Earnings per share were ₹13.25. The operating margin was 35.0%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is ERIS Lifesciences's market cap? ERIS Lifesciences Ltd's market capitalisation is ₹16,345 Cr at a share price of ₹1,177.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is ERIS Lifesciences performing? ERIS Lifesciences Ltd's share price has been falling for 40 weeks. In its latest quarter, revenue rose 12.6% and profit rose 39.6% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 16 weeks running (as of 3 November 2026). ### Will ERIS Lifesciences's share price go up? This page does not forecast ERIS Lifesciences Ltd's share price. What it shows instead: the share price is ₹1,177.70, and it has been falling for 40 weeks. Its P/E of 21.9× is higher than 12% of its own last 9 years (as of 3 November 2026). ### Who owns ERIS Lifesciences? Promoters own 54.7% of ERIS Lifesciences Ltd, foreign institutions 5.7%, domestic institutions 20.2% and the public 19.3% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 2.3 percentage points over 8 quarters (as of 3 November 2026). ### Where is ERIS Lifesciences in its business cycle? ERIS Lifesciences Ltd's FY26 operating margin was 36.0%, against a 13-year range of 19.0% to 38.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 35.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the ERIS Lifesciences story? The main question: yearly earnings per share moved +73.1% while the share price moved −26.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is ERIS Lifesciences a stock worth studying right now? What the numbers show: ERIS Lifesciences Ltd's earnings have grown faster than its share price. Earnings per share grew +73.1% in a year while the price moved −26.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a ERIS Lifesciences share price forecast for 2026? What management itself guided: H2 operating margin around 35% now at 36% with further gross and operating profit gains ahead. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.